Diflunisal Offlabel denied as not medically necessary by Humana?

Humana's specific coverage criteria for diflunisal offlabel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Diflunisal (Off-Label Use) as Not Medically Necessary

For off-label prescribing, Humana's medical-necessity review is typically more demanding than for on-label indications. When diflunisal is prescribed as a transthyretin stabilizer for hereditary or wild-type transthyretin amyloidosis (hATTR or ATTR-CM), Humana may deny medical necessity if: the diagnosis is not adequately documented in the submitted records; the patient has not been evaluated by a specialist with amyloidosis expertise; alternative therapies (including on-label transthyretin stabilizers or silencers) were not considered or addressed; or the clinical rationale for choosing diflunisal specifically over on-label options is absent from the documentation. The denial letter will cite the specific criterion(a) at issue; read it carefully before drafting the appeal.

## Why This Denial Is Appealable

Medical necessity denials for off-label use are appealed successfully when the prescriber's letter clearly establishes the diagnosis with objective evidence, documents the clinical reasoning for selecting diflunisal, addresses why on-label alternatives are not appropriate or were already tried, and ties the prescribing decision to the applicable professional society guidance. The appeal should be built around the patient's specific chart findings, not generic claims about the drug.

## Federal Appeal Framework

Under ACA Section 2719 and ERISA Section 503, this adverse determination is subject to mandatory internal appeal and independent external review. File the internal appeal within 180 days of the denial. After exhausting internal appeals, request external review within four months of the final internal denial. Expedited review is available when the standard timeline would seriously jeopardize the patient's health.

## Documentation to Gather

• Diagnosis confirmation: Genetic testing results (if hATTR), cardiac imaging reports, pathology if available, and specialist evaluation notes — all documenting the specific amyloidosis diagnosis.
• Specialty evaluation: Notes from a cardiologist, neurologist, or amyloidosis specialist supporting the diagnosis and the treatment plan.
• Prior treatment history: Documentation of any therapies previously tried, dates of use, and outcomes or reasons for discontinuation.
• Clinical severity documentation: Chart notes capturing functional status, organ involvement, and disease progression relevant to the clinical urgency of treatment.
• Prescriber medical-necessity letter: A comprehensive letter from the treating physician explaining: (a) the confirmed diagnosis and its severity; (b) why diflunisal is the appropriate agent for this patient; (c) how on-label alternatives were considered; and (d) a reference to the applicable professional society guideline or expert consensus (e.g., relevant AHA/ACC guideline or amyloidosis program consensus) without asserting specific numeric thresholds.

## Criteria-Mapping Structure

| Humana Medical-Necessity Criterion (verbatim) | Supporting Chart Documentation | |---|---| | [Each criterion from Humana's coverage policy] | [Specific chart entry, date, clinician, and finding that satisfies it] |

Obtain Humana's current medical policy for diflunisal or for transthyretin amyloidosis treatment directly from Humana's provider portal before submitting — the exact policy in effect on the date of service is the operative document.